Drug intelligence / Profile preview

recombinant hepatitis B vaccine + DTP-HB-Hib vaccine

Development stage: Unknown
Lead developer: Bio Farma
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

Recombinant Hepatitis B + DTP-HB-Hib is a combination vaccine regimen developed by PT Bio Farma (Indonesia) for the prevention of diphtheria, tetanus, pertussis, hepatitis B, and Haemophilus influenzae type b (Hib) infections in infants. The regimen consists of a birth dose of recombinant Hepatitis B vaccine (produced in the yeast Hansenula polymorpha) followed by a three-dose primary series of a pentavalent DTP-HB-Hib vaccine. The pentavalent component, marketed under the brand name Pentabio, contains diphtheria and tetanus toxoids, inactivated whole-cell pertussis bacteria, recombinant Hepatitis B surface antigen (HBsAg), and Hib conjugate. A Phase 3 bridging study (NCT04071379) completed in 2021 demonstrated that a new batch of the DTP-HB-Hib vaccine was immunogenic and well-tolerated in Indonesian infants when used in this priming regimen.

Brand names: Pentabio
Other names: DTP-HB-Hib (Bio Farma)pentavalent vaccine

Targets

PRNP (Cellular Prion Protein)HBsAg (Hepatitis B surface antigen)TT (Tetanus toxoid)Diphtheria toxin

Beyond the preview

Go deeper on recombinant hepatitis B vaccine + DTP-HB-Hib vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on recombinant hepatitis B vaccine + DTP-HB-Hib vaccine.

Explore the full profile